真实世界中现代系统治疗与临床标志物对转移性黑色素瘤治疗结局的影响
该研究前瞻性随访2010至2017年瑞典Karolinska大学医院的252例IV期黑色素瘤患者,比较一线免疫检查点抑制剂(ICIs)与MAPK抑制剂(MAPKis)的疗效,并分析临床变量与治疗反应及生存的关联。结果显示ICIs组中位无进展生存期(PFS)为6.8个月,MAPKis组为5.3个月;M分期增加、男性、低白蛋白、高乳酸脱氢酶(LDH)与较差结局相关。
要点
- 真实世界中ICIs与MAPKis对转移性黑色素瘤均有效。
- ICIs组中位PFS 6.8个月,MAPKis组5.3个月。
- 男性、M分期增加、低白蛋白、高LDH与较差治疗反应或生存相关。
核心结论
- 在真实世界转移性黑色素瘤人群中,ICIs和MAPKis均有效,并证实了既往报道的临床预后标志物的重要性。
- 白蛋白值可能与治疗结局相关,但需进一步验证。
研究设计与样本
- 前瞻性随访研究,纳入252例IV期黑色素瘤患者,2010年1月1日至2017年12月3日在瑞典Karolinska大学医院随访至2019年3月31日。
- 采用Cox回归分析无进展生存期(PFS)和总生存期(OS)的风险比(HR),逻辑回归估计治疗反应的比值比(OR)。
主要发现
- ICIs组(n=138)中位PFS为6.8个月,MAPKis组(n=114)为5.3个月。
- ICIs多变量分析中,M分期增加(OR 0.65;95%CI 0.45-0.94;P=0.022)和男性(OR 0.41;95%CI 0.19-0.90;P=0.027)与较低治疗反应显著相关。
- MAPKis多变量分析中,低基线白蛋白(OR 0.90;95%CI 0.83-0.98;P=0.019)和男性(OR 0.33;95%CI 0.12-0.93;P=0.036)与较低治疗反应相关。
- ICIs调整模型中,M分期增加(HR 1.34;95%CI 1.07-1.68;P=0.010)、LDH增加(HR 1.73;95%CI 1.19-2.50;P=0.004)和白蛋白降低(HR 1.06;95%CI 1.01-1.10;P=0.011)与较低PFS显著相关。
- MAPKis调整模型中,LDH增加(HR 1.44;95%CI 1.08-1.92;P=0.013)和白蛋白降低(HR 1.05;95%CI 1.02-1.09;P=0.005)与较低PFS相关。
临床怎么用
- 临床可参考基线白蛋白、LDH、M分期和性别等因素评估转移性黑色素瘤患者接受ICIs或MAPKis的预后。
- 白蛋白对治疗结局的影响需进一步验证,暂不宜作为独立决策指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The survival in metastatic melanoma has dramatically improved after the introduction of immune checkpoint- (ICIs) and MAPKinase inhibitors (MAPKis). OBJECTIVE: Our aim was to describe therapy response and survival in a real-world population as well as to assess the associations between clinical variables and therapy outcome for patients with metastatic melanoma receiving first-line ICIs or MAPKis. METHODS: A total of 252 patients with metastatic (stage IV) melanoma were prospectively followed between 1 January 2010 and 3 December 2017 with follow-up until 31 March 2019, at the Karolinska University Hospital, Sweden. Hazard ratios (HRs) for progression-free survival (PFS) and overall survival (OS) were analysed with Cox regression, and logistic regression was used to estimate odds ratios (ORs) for therapy response. RESULTS: Patients receiving ICIs (n = 138) experienced longer PFS compared to patients that received MAPKis (n = 114; median PFS for ICIs was 6.8 months, and median PFS for MAPKis was 5.3 months). In the multivariable analyses of clinical markers, increasing M-stage (OR 0.65; 95% CI 0.45-0.94; P = 0.022) and male sex (OR 0.41; 95% CI 0.19-0.90; P = 0.027) were significantly associated with lower response to ICIs. Lower baseline albumin levels (OR 0.90; 95% CI 0.83-0.98; P = 0.019) and male sex (OR 0.33; 95% CI 0.12-0.93; P = 0.036) were related with lower response to MAPKis. For ICIs, increasing M-stage (HR 1.34; 95% CI 1.07-1.68; P = 0.010), increasing LDH (HR 1.73; 95% CI 1.19-2.50; P = 0.004) and decreasing albumin (HR 1.06; 95% CI 1.01-1.10; P = 0.011) were significantly associated lower PFS in the adjusted model. The corresponding markers for MAPKis were increasing LDH (HR 1.44; 95% CI 1.08-1.92; P = 0.013) and decreasing albumin (HR 1.05; 95% CI 1.02-1.09; P = 0.005) for PFS. CONCLUSION: ICIs and MAPKis were effective in this real-world population, and we could confirm the importance of previously reported clinical prognostic markers. Albumin values may be associated with therapy outcome but need further validation.
引用
- Krakowski I, Bottai M, Häbel H, et al. Impact of modern systemic therapies and clinical markers on treatment outcome for metastatic melanoma in a real-world setting. J Eur Acad Dermatol Venereol. 2020. PMID: 32455474. doi:10.1111/jdv.16678
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。